Eltropag 25 mg (Eltrombopag) Tablets

Eltropag 25 contains Eltrombopag, a thrombopoietin receptor agonist that helps stimulate the body's natural platelet production process. It is primarily prescribed for patients experiencing persistently low platelet counts due to specific hematological conditions. By increasing platelet levels, this medicine may help reduce the risk of bleeding complications and improve overall treatment outcomes.

Therapeutic Uses:

• Management of chronic immune thrombocytopenia (ITP) in patients who have had an inadequate response to corticosteroids, immunoglobulins, or splenectomy.
• Treatment of severe aplastic anemia in selected patients under specialist supervision.
• Supportive treatment for thrombocytopenia associated with chronic hepatitis C to facilitate antiviral therapy when appropriate.
• Improvement of platelet counts in eligible patients with certain bone marrow disorders as determined by a healthcare professional.

Therapeutic Effects:

• Promotes the production and maturation of megakaryocytes in the bone marrow.
• Increases circulating platelet counts over time.
• May help decrease the frequency of bleeding episodes associated with severe thrombocytopenia.
• Supports continuation of essential therapies that require adequate platelet levels.
• Contributes to improved disease management and quality of life when used according to medical advice.

Active Ingredient:

• Eltrombopag Olamine equivalent to Eltrombopag 25 mg

Eltropag 25 is formulated with Eltrombopag, an orally administered thrombopoietin receptor agonist. The active ingredient works by binding to and activating thrombopoietin receptors, which play a key role in platelet formation.

Composition Information:

Each film-coated tablet contains:

• Eltrombopag 25 mg (as Eltrombopag Olamine)

The formulation may also contain pharmaceutical excipients required for tablet stability, manufacturing consistency, and patient acceptability. These inactive ingredients do not contribute directly to the therapeutic effect but support the overall quality and integrity of the dosage form.

Patients with known hypersensitivity to any component of the formulation should consult their healthcare provider before initiating treatment.

The dosage of Eltropag 25 should always be individualized based on the patient's clinical condition, platelet count response, age, and underlying diagnosis. Treatment must be initiated and monitored by a qualified healthcare professional experienced in managing hematological disorders.

General Administration Guidelines:

• Take the medicine exactly as prescribed by your physician.
• Swallow the tablet whole with water; do not crush or chew unless advised otherwise.
• The medication is generally taken once daily.
• Maintain a consistent schedule by taking it at the same time each day.

Important Administration Instructions:

• Avoid taking Eltropag simultaneously with dairy products, calcium-fortified foods, antacids, or supplements containing calcium, iron, magnesium, aluminum, selenium, or zinc, as these may reduce absorption.
• If such products are necessary, follow the time interval recommended by your healthcare provider.
• Regular monitoring of platelet counts and liver function tests may be required during treatment.

Missed Dose:

If a dose is missed, take the next scheduled dose at the usual time. Do not take a double dose to compensate for the missed tablet.

Overdose:

In the event of suspected overdose, seek immediate medical attention. Close monitoring of platelet levels and clinical status may be necessary.

Note: Dosage adjustments should only be made under medical supervision. Patients should never alter or discontinue treatment without consulting their healthcare provider.